Structural basis for activation of fatty acid-binding protein 4

被引:141
作者
Gillilan, Richard E. [1 ]
Ayers, Stephen D.
Noy, Noa
机构
[1] High Energy Synchrotron Source, Facil Cornell, Macromol Diffract, Ithaca, NY 14853 USA
[2] Cornell Univ, Div Nutr Sci, Ithaca, NY 14853 USA
[3] Case Western Reserve Univ, Sch Med, Dept Pharmacol, Cleveland, OH 44106 USA
关键词
allostery; FABP4; thiazolidinedione; aP2; import;
D O I
10.1016/j.jmb.2007.07.040
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Fatty acid-binding protein 4 (FABP4) delivers ligands from the cytosol to the nuclear receptor PPAR gamma in the nucleus, thereby enhancing the transcriptional activity of the receptor. Notably, FABP4 binds multiple ligands with a similar affinity but its nuclear translocation is activated only by specific compounds. To gain insight into the structural features that underlie the ligand-specificity in activation of the nuclear import of FABP4, we solved the crystal structures of the protein complexed with two compounds that 3 induce its nuclear translocation, and compared these to the apo-protein and to FABP4 structures bound to non-activating ligands. Examination of these Case Western Reserve structures indicates that activation coincides with closure of a portal loop phenylalanine side-chain, contraction of the binding pocket, a subtle shift in a helical domain containing the nuclear localization signal of the protein, and a resultant change in oligomeric state that exposes the nuclear received in revised form localization signal to the solution. Comparisons of backbone displacements induced by activating ligands with a measure of mobility derived from translation, libration, screw (TLS) refinement, and with a composite of slowest normal modes of the apo state suggest that the helical motion associated with the activation of the protein is part of the repertoire of the equilibrium motions of the apo-protein, i.e. that ligand binding does not induce the activated configuration but serves to stabilize it. Nuclear import of FABP4 can thus be understood in terms of the pre-existing equilibrium hypothesis of ligand binding. (c) 2007 Elsevier Ltd. All rights reserved.
引用
收藏
页码:1246 / 1260
页数:15
相关论文
共 46 条
[1]   Anisotropy of fluctuation dynamics of proteins with an elastic network model [J].
Atilgan, AR ;
Durell, SR ;
Jernigan, RL ;
Demirel, MC ;
Keskin, O ;
Bahar, I .
BIOPHYSICAL JOURNAL, 2001, 80 (01) :505-515
[2]   Continuous nucleocytoplasmic shuttling underlies transcriptional activation of PPARγ by FABP4 [J].
Ayers, Stephen D. ;
Nedrow, Katherine L. ;
Gillilan, Richard E. ;
Noy, Noa .
BIOCHEMISTRY, 2007, 46 (23) :6744-6752
[3]   Principal component analysis and long time protein dynamics [J].
Balsera, MA ;
Wriggers, W ;
Oono, Y ;
Schulten, K .
JOURNAL OF PHYSICAL CHEMISTRY, 1996, 100 (07) :2567-2572
[4]   PPARs: therapeutic targets for metabolic disease [J].
Berger, JP ;
Akiyama, TE ;
Meinke, PT .
TRENDS IN PHARMACOLOGICAL SCIENCES, 2005, 26 (05) :244-251
[5]   Direct channeling of retinoic acid between cellular retinoic acid-binding protein II and retinoic acid receptor sensitizes mammary carcinoma cells to retinoic acid-induced growth arrest [J].
Budhu, AS ;
Noy, N .
MOLECULAR AND CELLULAR BIOLOGY, 2002, 22 (08) :2632-2641
[6]   Physiological properties and functions of intracellular fatty acid-binding proteins [J].
Coe, NR ;
Bernlohr, DA .
BIOCHIMICA ET BIOPHYSICA ACTA-LIPIDS AND LIPID METABOLISM, 1998, 1391 (03) :287-306
[7]   Peroxisome proliferator-activated receptors: Nuclear control of metabolism [J].
Desvergne, B ;
Wahli, W .
ENDOCRINE REVIEWS, 1999, 20 (05) :649-688
[8]   Distinct roles for cellular retinoic acid-binding proteins I and II in regulating signaling by retinoic acid [J].
Dong, D ;
Ruuska, SE ;
Levinthal, DJ ;
Noy, N .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1999, 274 (34) :23695-23698
[9]   Coot:: model-building tools for molecular graphics [J].
Emsley, P ;
Cowtan, K .
ACTA CRYSTALLOGRAPHICA SECTION D-STRUCTURAL BIOLOGY, 2004, 60 :2126-2132
[10]   Peroxisome proliferator-activated receptor-γ figands for the treatment of breast cancer [J].
Fenner, MH ;
Elstner, E .
EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2005, 14 (06) :557-568